VivoSim Labs has regained compliance with Nasdaq's minimum stockholders' equity rule. The company received notice on August 4, 2026, that it now meets the $2.5 million requirement under Listing Rule 5550(b)(1). The turnaround follows a $5.0 million milestone payment from Eli Lilly and Company, the release of $1.0 million from escrow on July 22, 2026, and a financing on July 17, 2026, that brought in $4.0 million in gross proceeds. As of August 3, 2026, VivoSim's cash on hand was approximately $10.1 million, and it reiterated guidance for over 500% revenue growth in fiscal year 2027.
VivoSim Labs, Inc.Regained Nasdaq compliance after equity boost, with cash and revenue guidance positive.
Eli Lilly and Company